SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3597)10/23/2018 4:16:35 PM
From: tuck  Read Replies (1) | Respond to of 3661
 
According to Roche's pipeline chart: "RG7461 is a targeted immunocytokine combining an engineered interleukin-2 variant (IL2v) with an antibody against fibroblast activation protein (FAP), a protein expressed in several cancers. A phase I clinical trial evaluating RG7461 in solid tumours is ongoing."


Dunno what the heck is going on with the nomenclature here.


Cheers, Tuck



To: scaram(o)uche who wrote (3597)10/23/2018 4:45:28 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3661
 
at NIH/NCI it is listed as RO6874261 (Code # RG7461 as pipeline compound...Roche WP).

cancer.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News